Combination therapy with MEK inhibitor and CDK4/6 inhibitor to treat pancreatic cancer
AssigneeMemorial Sloan Kettering Cancer Center
InventorsMarcus Ruscetti, John P. Morris, IV, Scott Lowe
Life of this patent
Estimating the term…
Abstract
The present technology provides methods for treating pancreatic cancer using a MEK inhibitor and a CDK4/6 inhibitor. Also disclosed herein are methods for increasing patient responsiveness to chemotherapeutic and/or immunotherapeutic regimes for pancreatic cancer. Kits for use in practicing the methods are also provided.
Claims11
A method for increasing the responsiveness of a pancreatic cancer patient to at least one chemotherapeutic agent or at least one immunotherapeutic agent comprising administering to the patient an effective amount of a MEK inhibitor and an effective amount of a CDK4/6 inhibitor.
A kit comprising a MEK inhibitor, a CDK4/CDK6 inhibitor, and instructions for treating pancreatic cancer.
Dependencies are inferred from the claim text.